We use cookies for a better user experience. Read our Privacy Policy

I Agree

Parkinson’s Disease Therapeutics Market

Parkinson’s Disease Therapeutics Market (Drug Class - Levodopa Combination, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors; Route of Administration - Oral, Transdermal, Subcutaneous, Intestinal Infusion; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Parkinson’s Disease Therapeutics Market - Snapshot

The global Parkinson’s disease therapeutics market is growing with high prevalence and rise in incidences of Parkinson’s disease across the developed countries. The global Parkinson’s disease therapeutics market was valued at US$ 2.18 Bn in 2016 and is projected to witness cumulative annual growth rate (CAGR) of more than 10.9% from 2017 to 2025 to exceed the US$ 5.24 Bn by 2025. The global Parkinson’s disease therapeutics market is witnessing a relatively high growth owing to rise in awareness regarding Parkinson’s disease, rapidly growing geriatric population, promising pipeline drugs, and new product launches.

Parkinson’s disease is a progressive neurodegenerative disorder that affects the dopamine producing nerve cells in the brain. Parkinson’s disease primarily causes tremors, muscle stiffness, improper motor movements, and gait and balance problems. Secondary symptoms of Parkinson’s disease include anxiety, depression, and dementia. The exact cause of Parkinson’s disease is not known; it predominantly affects the older people who are above 50 years of age. Men are one-and-half times more affected by the disease than women. According to Parkinson’s Foundation based in the U.S., it is estimated that worldwide around 7 to 10 million people are affected by disease and every year around 60,000 Americans are diagnosed with it. High prevalence and rise in incidence rates of Parkinson’s disease in developed countries are driving the growth of the global Parkinson’s disease therapeutics market. Also, increase in awareness about Parkinson’s disease and high clinical R&D budget by the governments and non-profit organizations are projected to fuel the growth of the Parkinson’s therapeutics market during the forecast period. The promising product pipeline represents the potential business development opportunities during the forecast period. In the U.S., there are around 10 different drugs under clinical pipeline studies in phase 3 for treating different symptoms of Parkinson’s disease. However, patent expiration of key branded drugs and side-effects associated with therapeutic drugs are anticipated to limit the growth of the Parkinson’s disease therapeutics market during the forecast period.

parkinsons-disease-therapeutics-market.jpg

Till date, there is no permanent cure available for treating Parkinson’s disease. However, medications such as levodopa combination therapy, dopamine agonists, MAO-B inhibitors, COMT inhibitors, cholinesterase inhibitors, and amantadine drugs are used to treat the different symptoms associated with the disease. Levodopa combination therapy is highly recommended and widely used for treating the motor symptoms of Parkinson’s disease

The global Parkinson’s disease therapeutics market can be divided into four segments based on drug class, route of administration, distribution channel, and geography. In terms of drug class, the global Parkinson’s disease therapeutics market can be segmented into levodopa combination therapy, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and others. The other drug class includes cholinesterase inhibitors, amantadine, antipsychotic drugs, and vassopressant drugs. Levodopa combination therapy dominated the global Parkinson’s disease therapeutics market in 2016, holding more than 32% share of the market. The segment is projected to grow at a moderate pace during the forecast period and is poised to gain market share by the end of 2025. Levodopa combination therapy is considered a highly effective treatment for controlling the motor symptoms throughout the stages of Parkinson’s disease.

In terms of route of administration, the global Parkinson’s disease therapeutics market can be classified into oral, transdermal, subcutaneous, intestinal infusion, and others. The oral route of administration accounted for the leading share of the global market. The segment is projected to continue its dominance throughout the forecast period. The recent launch of Duopa in the U.S. has contributed to significant share of the intestinal infusion segment in the global market. The other routes of administration include sublingual film and inhalation. The anticipated launch of pipeline drugs administered through inhalation and sub-lingual route is likely to gain market share by the end of 2025. Distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment dominated the global Parkinson’s disease therapeutics market in 2016 and is likely to gain market share by the end of 2025.

Geographically, the Parkinson’s disease therapeutics market can be categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe accounted for the largest share of the global Parkinson’s disease therapeutics market in 2016, followed by North America with a substantial market share. High level of awareness, increase in funding for research and grants, favorable medical reimbursement policies, high prevalence of Parkinson’s disease, rapidly growing geriatric population, and promising clinical pipeline products have contributed to the key share of Europe in the Parkinson’s disease therapeutics market. Europe is a highly attractive market and is expected to expand at a significant CAGR during the forecast period. The Parkinson’s disease therapeutics market in Asia Pacific is poised to grow at a moderate growth rate. A major share of the Parkinson’s disease therapeutics market is captured by Japan and China in Asia Pacific, primarily due to the large base of elderly people affected with Parkinson’s disease in these countries.

The global Parkinson’s disease therapeutics market is consolidated with a few companies accounting for majority of its share. Leading players operating in the global Parkinson’s disease therapeutics market include Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., and UCB Inc., which exhibit wide geographical outreach. Manufacturers are adopting new product commercialization in the international market to tap the unmet needs of Parkinson’s disease. Other prominent players operating in the global market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.

The global Parkinson’s disease therapeutics market is segmented as follows:

Drug Class

  • Levodopa Combination
  • Dopamine Agonists
  • MAO-B Inhibitors
  • COMT Inhibitors
  • Others

Route of Administration

  • Oral
  • Transdermal
  • Subcutaneous
  • Intestinal Infusion
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
Parkinson’s Disease Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Parkinson’s Disease Therapeutics Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
5.5. Global Parkinson’s Disease Therapeutics Market Outlook
5.6. Global Prevalence of Parkinson’s Disease
5.7. Pipeline Analysis

Chapter 6 Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       6.3.1. Levodopa Combination
       6.3.2. Dopamine Agonists
       6.3.3. MAO-B Inhibitors
       6.3.4. COMT Inhibitors
       6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class

Chapter 7 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Key Findings
7.2. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       7.2.1. Oral
       7.2.2. Transdermal
       7.2.3. Subcutaneous
       7.2.4. Intestinal Infusion
       7.2.5. Others
7.3. Market Attractiveness Analysis, by Route of Administration
7.4. Key Trends

Chapter 8 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
       8.3.1. Hospital Pharmacy
       8.3.2. Retail Pharmacy
       8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel

Chapter 9 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
       9.3.1. North America
       9.3.2. Europe
       9.3.3. Asia Pacific
       9.3.4. Latin America
       9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region

Chapter 10 North America Parkinson’s Disease Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
       10.2.1. U.S.
       10.2.2. Canada
10.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       10.3.1. Levodopa Combination
       10.3.2. Dopamine Agonists
       10.3.3. MAO-B Inhibitors
       10.3.4. COMT Inhibitors
       10.3.5. Others
10.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       10.4.1. Oral
       10.4.2. Transdermal
       10.4.3. Subcutaneous
       10.4.4. Intestinal Infusion
       10.4.5. Other
10.5. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
       10.5.1. Hospital Pharmacy
       10.5.2. Retail Pharmacy
       10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
       10.6.1. By Country
       10.6.2. By Drug Class
       10.6.3. By Route of Administration
       10.6.4. By Distribution Channel

Chapter 11 Europe Parkinson’s Disease Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
       11.2.1. Germany
       11.2.2. U.K.
       11.2.3. France
       11.2.4. Italy
       11.2.5. Spain
       11.2.6. Rest of Europe
11.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       11.3.1. Levodopa Combination
       11.3.2. Dopamine Agonists
       11.3.3. MAO-B Inhibitors
       11.3.4. COMT Inhibitors
       11.3.5. Others
11.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       11.4.1. Oral
       11.4.2. Transdermal
       11.4.3. Subcutaneous
       11.4.4. Intestinal Infusion
       11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
       11.5.1. Hospital Pharmacy
       11.5.2. Retail Pharmacy
       11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
       11.6.1. By Country
       11.6.2. By Drug Class
       11.6.3. By Route of Administration
       11.6.4. By Distribution Channel

Chapter 12 Asia Pacific Parkinson’s Disease Therapeutics Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
       12.3.1. China
       12.3.2. India
       12.3.3. Japan
       12.3.4. Australia & New Zealand
       12.3.5. Rest of Asia Pacific
12.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       12.4.1. Levodopa Combination
       12.4.2. Dopamine Agonists
       12.4.3. MAO-B Inhibitors
       12.4.4. COMT Inhibitors
       12.4.5. Others
12.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       12.5.1. Oral
       12.5.2. Transdermal
       12.5.3. Subcutaneous
       12.5.4. Intestinal Infusion
       12.5.5. Others
12.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
       12.6.1. Hospital Pharmacy
       12.6.2. Retail Pharmacy
       12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
       12.7.1. By Country
       12.7.2. By Drug Class
       12.7.3. By Route of Administration
       12.7.4. By Distribution Channel

Chapter 13 Latin America Parkinson’s Disease Therapeutics Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
       13.3.1. Brazil
       13.3.2. Mexico
       13.3.3. Rest of Latin America
13.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       13.4.1. Levodopa Combination
       13.4.2. Dopamine Agonists
       13.4.3. MAO-B Inhibitors
       13.4.4. COMT Inhibitors
       13.4.5. Others
13.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       13.5.1. Oral
       13.5.2. Transdermal
       13.5.3. Subcutaneous
       13.5.4. Intestinal Infusion
       13.5.5. Others
13.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
       13.6.1. Hospital Pharmacy
       13.6.2. Retail Pharmacy
       13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
       13.7.1. By Country/Sub-region
       13.7.2. By Drug Class
       13.7.3. By Route of Administration
       13.7.4. By Distribution Channel

Chapter 14 Middle East & Africa Parkinson’s Disease Therapeutics Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
       14.3.1. GCC Countries
       14.3.2. South Africa
       14.3.3. Rest of Middle East & Africa
14.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       14.4.1. Levodopa Combination
       14.4.2. Dopamine Agonists
       14.4.3. MAO-B Inhibitors
       14.4.4. COMT Inhibitors
       14.4.5. Others
14.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       14.5.1. Oral
       14.5.2. Transdermal
       14.5.3. Subcutaneous
       14.5.4. Intestinal Infusion
       14.5.5. Others
14.6. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
       14.6.1. Hospital Pharmacy
       14.6.2. Retail Pharmacy
       14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
       14.7.1. By Country/Sub-region
       14.7.2. By Drug Class
       14.7.3. By Route of Administration
       14.7.4. By Distribution Channel

Chapter 15 Competition Landscape
15.1. Global Parkinson’s Disease Therapeutics Market Share, by Company, 2016
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
       15.3.1. AbbVie, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       15.3.2. UCB Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       15.3.3. Merck & Co., Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.4. Valeant Pharmaceuticals International, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.5. Novartis AG

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.6. Boehringer Ingelheim GmbH.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.7. GlaxoSmithKline plc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.8. Teva Pharmaceutical Industries Ltd.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.9. STADA Arzneimittel AG.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.10. Impax Laboratories, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.11. F. Hoffmann-La Roche Ltd.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

List of Tables

Table 01: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 03: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 04: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 05: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 06: North America Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 07: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 08: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 09: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 10: Europe Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 11: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 12: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Asia Pacific Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 16: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 18: Latin America Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 19: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 20: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 22: Middle East & Africa  Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 23: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 24: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Figures

Figure 01: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Market Value Share, by Drug Class (2016)
Figure 03: Market Value Share, by Route of Administration (2016)
Figure 04: Market Value Share, by Distribution Channel (2016)
Figure 05: Market Value Share, by Region (2016)
Figure 06: Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Drug Class, 2016 and 2025
Figure 07: Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 08: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Levodopa Combination, 2015–2025
Figure 09: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Dopamine Agonists, 2015–2025
Figure 10: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Monoamine Oxidase B Inhibitors (MAO-B Inhibitors), 2015–2025
Figure 11: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Catechol-O-methyltransferase (COMT) Inhibitors, 2015–2025
Figure 12: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 13: Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Route of Administration, 2016 and 2025
Figure 14: Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 15: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2015–2025
Figure 16: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Transdermal, 2015–2025
Figure 17: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous, 2015–2025
Figure 18: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intestinal Infusion, 2015–2025
Figure 19: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 20: Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Distribution Channel, 2016 and 2025
Figure 21: Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 22: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
Figure 23: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
Figure 24: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015–2025
Figure 25: Global Parkinson's Disease Therapeutics Market Value Share Analysis, by Region, 2016 and 2025 
Figure 26: Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Region, 2017–2025
Figure 27: North America Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 28: North America Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country , 2016 and 2025
Figure 29: North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 30: North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 31: North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 32: North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 33: North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 34: North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 35: North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 36: Europe Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 37: Europe Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
Figure 38: Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 39: Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 40: Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 41: Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 42:  Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 43: Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 44: Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 45: Asia Pacific Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 46: Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
Figure 47: Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 48: Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 49: Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 50: Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 51: Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 52: Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 53: Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 54: Latin America Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 55: Latin America Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
Figure 56: Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 57: Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 58: Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 59: Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 60: Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 61: Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 62: Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 63: Middle East & Africa Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 64: Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
Figure 65: Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 66: Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 67: Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 68: Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 69: Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 70: Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 71: Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 72: Global Parkinson’s Disease Therapeutics Market Share Analysis, by Company (2016)
Figure 73: AbbVie, Inc.’s Breakdown of Net Sales, by Region
Figure 74: AbbVie, Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 75: AbbVie, Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 77: UCB Inc.’s Breakdown of Net Sales, by Therapeutic Area
Figure 79: UCB Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 76: UCB Inc.’s Breakdown of Net Sales, by Region
Figure 78 : UCB Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 79: UCB Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 80: Merck & Co., Inc.’s  Sales Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 81: Merck & Co., Inc.’s  Net Sales Breakdown, by Region, 2016
Figure 82: Merck & Co., Inc.’s Breakdown of Net Sales, by Business Segment, 2016
Figure 83: Merck & Co., Inc.’s Research and Development Expenditure (US$ Mn) and Intensity (%), 2016 and 2015
Figure 84: Valeant Pharmaceuticals International, Inc.’s Breakdown of Net Sales, by Region, 2016
Figure 85: Valeant Pharmaceuticals International, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
Figure 86: Valeant Pharmaceuticals International, Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 87: Novartis AG’s Breakdown of Net Sales, by Region
Figure 88: Novartis AG’s Breakdown of Net Sales, by Business Segment
Figure 89: Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2016
Figure 90: Novartis AG’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 91: Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 92: Boehringer Ingelheim GmbH’s Breakdown of Net Sales, by Business and Business Segment Level, 2016
Figure 93: Boehringer Ingelheim GmbH’s Breakdown of Net Sales, by Region (Company Level), 2016
Figure 94: Boehringer Ingelheim GmbH’s R&D Expenditure (US$ Bn), 2013–2016
Figure 95: GSK’s Sales Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
Figure 96: GSK’s Breakdown of GSK’s Pharmaceutical’s R&D Expenditure (US$ Bn)
Figure 97: GSK’s Breakdown of GSK’s Net Sales, by Region, 2016
Figure 98: GSK’s Breakdown of GSK’s Net Sales, by Business Segment, 2016
Figure 99: Teva Pharmaceutical Industries Ltd.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 100: Teva Pharmaceutical Industries Ltd.’s R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 101: Teva Pharmaceutical Industries Ltd.’s Breakdown of Net Sales, by Region 2016
Figure 102: Teva Pharmaceutical Industries Ltd.’s Breakdown of Net Sales, (Overall Company Level), 2016
Figure 103: STADA’s Breakdown of Net Sales, by Region, 2016
Figure104: STADA’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
Figure 105: STADA’s Breakdown of Net Sales, by Business Segment Level, 2016
Figure 106: Impax’s Breakdown of Net Sales, by Region, 2016
Figure 107: Impax’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
Figure 108: Impax’s Breakdown of Net Sales, by Business Segment Level, 2016
Figure 109: F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 110: F. Hoffmann-La Roche AG Marketing and R&D Expenses, 2015–2016
Figure 111: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division, 2016
Figure 112: F. Hoffmann-La Roche AG Breakdown of Net Sales (Pharmaceutical Segment), by Region, 2016

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

900

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved